Search

Your search keyword '"Perez-Segura, P"' showing total 177 results

Search Constraints

Start Over You searched for: Author "Perez-Segura, P" Remove constraint Author: "Perez-Segura, P"
177 results on '"Perez-Segura, P"'

Search Results

1. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM)

2. A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

4. Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

5. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

6. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

7. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

8. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk

9. Identification of the initial molecular changes in response to circulating angiogenic cells-mediated therapy in critical limb ischemia

10. Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients

18. 871P Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study

19. Association of Time of Day With Outcomes Among Patients Triaged for a Suspected Severe Stroke in Nonurban Catalonia

20. Workflows and Outcomes in Patients With Suspected Large Vessel Occlusion Stroke Triaged in Urban and Nonurban Areas

21. Polygenic risk modeling for prediction of epithelial ovarian cancer risk (vol 30, pg 349, 2021)

22. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

23. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

24. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

25. Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy

26. Splicing predictions, minigene analyses, and ACMG-AMP clinical classification of 42 germline PALB2 splice-site variants

32. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers

37. Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

38. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.

39. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01)

41. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness.

42. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

44. 678P Real-world evidence of first-line cetuximab (CX) plus paclitaxel (PX) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)

48. Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics. (Original Article)

49. Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial

50. EXTENDING ADJUVANT TEMOZOLOMIDE LONGER THAN SIX CYCLES DOESN'T ADD ANY BENEFIT TO GLIOBLASTOMA PATIENTS ACCORDING TO THE RANDOMIZED GEINO-014 TRIAL

Catalog

Books, media, physical & digital resources